Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

Company Overview

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key Stats

• Today's Range: $1.75 to $1.86
• 50-Day Range: $1.79 to $3.27
• 52-Week Range: $1.72 to $5.09
• Volume: 995,293 shs
• Average Volume: 324,811 shs
• Market Capitalization: $111.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.33
• Consensus Rating: Buy

Acumen Pharmaceuticals Stock Analysis - MarketRank™

Acumen Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 386th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Acumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Acumen Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.56) to ($1.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acumen Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acumen Pharmaceuticals is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acumen Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.09% of the float of Acumen Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Acumen Pharmaceuticals has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acumen Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Acumen Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.09% of the float of Acumen Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Acumen Pharmaceuticals has recently decreased by 5.44%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.97

News Sentiment

Acumen Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for ABOS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Acumen Pharmaceuticals is held by insiders.

Percentage Held by Institutions

71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABOS Stock Analysis - Frequently Asked Questions

How have ABOS shares performed this year?

Acumen Pharmaceuticals' stock was trading at $3.84 at the start of the year. Since then, ABOS stock has decreased by 51.8% and is now trading at $1.85.
View the best growth stocks for 2024 here.

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.14.

When did Acumen Pharmaceuticals IPO?

Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.

Who are Acumen Pharmaceuticals' major shareholders?

Acumen Pharmaceuticals' top institutional shareholders include Franklin Resources Inc. (5.91%), FMR LLC (3.38%), Geode Capital Management LLC (1.44%) and Jane Street Group LLC. Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Derek M Meisner, Russell Barton and Jeffrey L Ives.
View institutional ownership trends.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Acumen Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABOS
• CUSIP: N/A
• CIK: 1576885
• Web: www.acumenpharm.com
• Phone: 434-297-1000
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.33
• High Stock Price Target: $15.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +404.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-52,370,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.99%
• Return on Assets: -27.99%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 10.43
• Quick Ratio: 10.43

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.61 per share
• Price / Book: 0.40

Miscellaneous

• Outstanding Shares: 60,080,000
• Free Float: 55,814,000
• Market Cap: $111.15 million
• Optionable: Optionable
• Beta: -0.07